BeOne Selling General Administrative from 2010 to 2025
| ONC Stock | 210.08 4.74 2.31% |
Selling General Administrative | First Reported 2010-12-31 | Previous Quarter 1.7 B | Current Value 1.2 B | Quarterly Volatility 383.9 M |
Check BeOne Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BeOne Medicines' main balance sheet or income statement drivers, such as Tax Provision of 35.3 M, Net Interest Income of 89.4 M or Interest Income of 1.6 M, as well as many indicators such as . BeOne financial statements analysis is a perfect complement when working with BeOne Medicines Valuation or Volatility modules.
BeOne | Selling General Administrative |
Latest BeOne Medicines' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of BeOne Medicines over the last few years. It is BeOne Medicines' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BeOne Medicines' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
BeOne Selling General Administrative Regression Statistics
| Arithmetic Mean | 831,691,716 | |
| Geometric Mean | 767,228,429 | |
| Coefficient Of Variation | 46.16 | |
| Mean Deviation | 318,334,109 | |
| Median | 600,176,000 | |
| Standard Deviation | 383,943,078 | |
| Sample Variance | 147412.3T | |
| Range | 1.1B | |
| R-Value | 0.78 | |
| Mean Square Error | 63071.9T | |
| R-Squared | 0.60 | |
| Significance | 0.0004 | |
| Slope | 62,501,234 | |
| Total Sum of Squares | 2211184.3T |
BeOne Selling General Administrative History
About BeOne Medicines Financial Statements
BeOne Medicines stakeholders use historical fundamental indicators, such as BeOne Medicines' Selling General Administrative, to determine how well the company is positioned to perform in the future. Although BeOne Medicines investors may analyze each financial statement separately, they are all interrelated. For example, changes in BeOne Medicines' assets and liabilities are reflected in the revenues and expenses on BeOne Medicines' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BeOne Medicines. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 1.7 B | 1.2 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BeOne Medicines offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BeOne Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Beone Medicines Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Beone Medicines Stock:Check out the analysis of BeOne Medicines Correlation against competitors. For information on how to trade BeOne Stock refer to our How to Trade BeOne Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeOne Medicines. If investors know BeOne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeOne Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.19) | Revenue Per Share 225.239 | Quarterly Revenue Growth 0.395 | Return On Assets (0.1) | Return On Equity |
The market value of BeOne Medicines is measured differently than its book value, which is the value of BeOne that is recorded on the company's balance sheet. Investors also form their own opinion of BeOne Medicines' value that differs from its market value or its book value, called intrinsic value, which is BeOne Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeOne Medicines' market value can be influenced by many factors that don't directly affect BeOne Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeOne Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if BeOne Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeOne Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.